Wayrilz is a medicine used to treat immune thrombocytopenia, a disease in which the patient’s immune system destroys platelets (components in the blood that help it to clot).It is used in adults for whom treatment with other medicines has not worked. Immune thrombocytopenia is rare, and Wayrilz was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 4 June 2020. Further information on the orphan designation can be found on the EMA [website](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2278). Wayrilz contains the active substance rilzabrutinib.
Therapeutic Indication
### Therapeutic indication Wayrilz is indicated for the treatment of immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (see section 5.1)
Therapeutic Area (MeSH)
ATC Code
Not yet assigned
ATC Item
xnot yet assigned
Pharmacotherapeutic Group
N/A
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| rilzabrutinib | N/A | Rilzabrutinib |
EMA Name
Wayrilz
Medicine Name
Wayrilz
Aliases
N/ANo risk management plan link.
